Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
暂无分享,去创建一个
R. Kerbel | C. Sigman | G. Kelloff | R. Ruddon | John W. Park | D. Slamon | D. Parkinson | B. Chabner | J. Barrett | Jonathan C Peck | R. W. Ruddon
[1] D. Hanahan,et al. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. , 1985, Nature.
[2] R. Gale,et al. Chronic myeloid leukemia. , 1992, The American journal of medicine.
[3] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[4] P. Leder,et al. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.
[5] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[6] O. Witte,et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.
[7] W. Gullick,et al. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. , 1991, British medical bulletin.
[8] R. Dickson,et al. Genes, oncogenes, and hormones : advances in cellular and molecular biology of breast cancer , 1991 .
[9] P. Carter,et al. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. , 1992, Cancer treatment and research.
[10] E. Canaani,et al. Chronic myelogenous leukemia: biology and therapy. , 1993, Leukemia.
[11] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[12] P. Ravdin,et al. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. , 1995, Gene.
[13] D Tripathy,et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] V. Steele,et al. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[15] Thomas Ried,et al. Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping , 1997, Nature Genetics.
[16] Takayuki Asahara,et al. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.
[17] S. Fox,et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.
[18] F. Révillion,et al. ERBB2 oncogene in human breast cancer and its clinical significance. , 1998, European journal of cancer.
[19] A. Weiss,et al. Detection and characterization of carcinoma cells in the blood. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[20] D A Berry,et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. , 1998, Journal of the National Cancer Institute.
[21] J. Herman,et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.
[22] A. Harris,et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? , 1999, Journal of the National Cancer Institute.
[23] R. Hoffman. Green fluorescent protein to visualize cancer progression and metastasis. , 1999, Methods in enzymology.
[24] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] W. Lau,et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. , 1999, Cancer research.
[26] D. Hanahan,et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.
[27] J. Herman,et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.
[28] B. Druker,et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.
[29] J. Folkman,et al. The Hemostatic System as a Regulator of Angiogenesis* , 2000, The Journal of Biological Chemistry.
[30] M. Fernö,et al. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] Shigeyoshi Itohara,et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis , 2000, Nature Cell Biology.
[32] Gabriele Bergers,et al. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.
[33] S. Paik,et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. , 2000, Journal of the National Cancer Institute.
[34] R. Kerbel,et al. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. , 2000, European journal of cancer.
[35] J. Folkman,et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.
[36] S. Baruchel,et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. , 2000, The Journal of clinical investigation.
[37] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[38] K. Kinzler,et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. , 2001, Cancer research.
[39] B. Druker,et al. Chronic myeloid leukemia: current treatment options. , 2001, Blood.
[40] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[41] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[42] S. Rafii,et al. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.
[43] Christopher B Umbricht,et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR , 2001, The Lancet.
[44] I. Smith,et al. Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studies , 2001, Anti-cancer drugs.
[45] J. Isner,et al. Bone Marrow as a Source of Endothelial Cells for Natural and Iatrogenic Vascular Repair , 2001, Annals of the New York Academy of Sciences.
[46] A. Goldhirsch,et al. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. , 2001, Blood.
[47] R. Perez-soler. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced-EGFR-expressing, non-small cell lung cancer (NSCLC) , 2001 .
[48] R. Brekken,et al. VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[49] G. Doyle,et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. , 2001, Urology.
[50] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.
[51] J. Baselga,et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] J. Folkman,et al. Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.
[53] Sigrid Stroobants,et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. , 2002, European journal of cancer.
[54] R. Larson,et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.
[55] L. Ellis,et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Peter Bohlen,et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. , 2002, Cancer research.
[57] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[58] W. Carney,et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] E. Scarpi,et al. Vascular endothelial growth factor and prognosis in patients with node‐negative breast cancer , 2002, International journal of cancer.
[60] M. Mottolese,et al. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[61] P. Rosée,et al. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective , 2002, Leukemia.
[62] E. Rowinsky,et al. The ErbB receptor family: a therapeutic target for cancer. , 2002, Trends in molecular medicine.
[63] M. Baccarani,et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.
[64] J. Baselga,et al. HER-Targeted Tyrosine-Kinase Inhibitors , 2002, Oncology.
[65] Koichi Hattori,et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.
[66] T. Jacks,et al. Cancer Modeling in the Modern Era Progress and Challenges , 2002, Cell.
[67] O. Alonso,et al. Predictive value of 99mTc sestamibi scintigraphy in the evaluation of doxorubicin based chemotherapy response in patients with advanced breast cancer , 2002 .
[68] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[69] M. Jeffers,et al. An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma. , 2002, International journal of oncology.
[70] A. Harris,et al. Drug inhibition of angiogenesis. , 2002, Current opinion in pharmacology.
[71] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] David H. Johnson. Gefitinib (Iressa) trials in non-small cell lung cancer. , 2003, Lung cancer.
[73] R. Kerbel. Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved , 2003, Cancer biology & therapy.
[74] J. Baselga,et al. Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[75] J. Grandis,et al. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer , 2003, Expert review of anticancer therapy.
[76] W. Kaelin,et al. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. , 2003, The New England journal of medicine.
[77] R. Herbst. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. , 2003, Seminars in oncology.
[78] R. Jain,et al. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. , 2003, Blood.
[79] F. Kabbinavar,et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] S. Hilsenbeck,et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. , 2004, Journal of the National Cancer Institute.
[81] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[82] P. Bonomi. Clinical studies with non-iressa EGFR tyrosine kinase inhibitors. , 2003, Lung cancer.
[83] Giovanni Martinelli,et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[84] M. Sliwkowski,et al. Preclinical studies with Erlotinib (Tarceva). , 2003, Seminars in oncology.
[85] R. Natale. O-244 Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: Predicting response to gefitinib, an EGFR kinase inhibitor , 2003 .
[86] B. Druker. Imatinib alone and in combination for chronic myeloid leukemia. , 2003, Seminars in hematology.
[87] J. Baselga,et al. Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with genfinitib (ZD1839) , 2003 .
[88] M. Deininger. Cytogenetic studies in patients on imatinib. , 2003, Seminars in hematology.
[89] S. Ho,et al. Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer. , 2003, Cancer letters.
[90] M. Hidalgo,et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[91] J. Ford,et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[92] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[93] Manuel Hidalgo,et al. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. , 2003, Journal of the National Cancer Institute.
[94] S. Goodison,et al. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[95] Lesley Seymour,et al. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. , 2003, The Lancet. Oncology.
[96] R. Bast,et al. Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer , 2004, Clinical Cancer Research.
[97] P. Harari,et al. Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? , 2004, International journal of radiation oncology, biology, physics.
[98] Adam P Dicker,et al. Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer , 2004, Clinical Cancer Research.
[99] F. Penault-Llorca,et al. Prognostic Value of Residual Node Involvement in Operable Breast Cancer after Induction Chemotherapy , 2002, Breast Cancer Research and Treatment.
[100] P. Carter,et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies , 1993, Cancer Immunology, Immunotherapy.